Nuevolution is collaborating with Duke University, the Howard Hughes Medical Institute and Lexicon Pharmaceuticals for the investigation of the biological mechanism of action of a specified GPCR drug target. The Principal Investigator for Duke University and the Howard Hughes Medical Institute is Robert J. Lefkowitz, a Duke faculty member, HHMI employee and Nobel Laureate in Chemistry 2012.
Nuevolution will provide access to its proprietary Chemetics technology for small molecule drug discovery and Nuevolution and Lexicon will provide access to selected chemical libraries created using the Chemetics technology. Hundreds of millions of diverse small molecules will be screened to discover compounds with certain novel and unique properties against the GPCR drug target.
“We have used the Chemetics technology successfully to identify novel chemotypes for our internal programs and are enthusiastic about exploring the utility of our DNA-tagged libraries of diverse chemical compounds in the screening of GPCRs,” said Brian P. Zambrowicz, Ph.D., executive vice president and chief scientific officer of Lexicon.
“If successful, this project may cast new light on the mechanism of action of GPCRs,” said Thomas Franch, chief scientific officer of Nuevolution.